Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Detection of pancreatic ductal adenocarcinoma-associated proteins in serum

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer types, partly because it is frequently identified at an advanced stage, when surgery is no longer feasible. Therefore, early detection using minimally invasive methods such as blood tests may improve outcomes. However, studies to discover molecular signatures for the early detection of PDAC using blood tests have only been marginally successful. In the current study, a quantitative glycoproteomic approach via data-independent acquisition mass spectrometry (DIA-MS) was utilized to detect glycoproteins in 29 patient-matched PDAC tissues and sera. Total of 892 glycopeptides originated from 141 glycoproteins had PDAC associated changes beyond normal variation. We further evaluated the specificity of these serum detectable glycoproteins by comparing their abundance in 53 independent PDAC patient sera and 65 cancer-free controls. The PDAC tissue-associated glycoproteins we have identified represent an inventory of serum detectable PDAC glycoproteins as candidate biomarkers that can be potentially used for the detection of PDAC using blood tests.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

SUBMITTER: Yingwei HU

LAB HEAD: Hui Zhang

PROVIDER: PXD039273 | Pride | 2023-12-19

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	JHU_LM2_10022_85.raw	Raw
	JHU_LM2_10022_85_G.raw	Raw
	JHU_LM2_18029_81.raw	Raw
	JHU_LM2_18029_81_G.raw	Raw
	JHU_LM2_19327_89.raw	Raw

Items per page:

1 - 5 of 240

Similar Datasets

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

Profiling of Pancreatic Ductal Adenocarcinoma using serum lipidomics

Project description:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer due to its rapid progression, marked potential for metastasis and the difficulty in diagnosis1-3. However, there are no effective liquid tests currently available for PDAC detection besides CA19-9. Here we introduce a noninvasive detection approach that employs machine learning plus untargeted and targeted serum lipidomics to establish an accurate method to detect PDAC.

2021-07-05 | MSV000087756 | MassIVE

GNPS - Profiling of Pancreatic Ductal Adenocarcinoma using serum lipidomics

2021-07-05 | MSV000087756 | GNPS

Autoimmune antigen and serum factor antigen reactivity in a cohort of patients with systemic lupus erythematosus (SLE) and healthy controls from the ABCoN cohort.

2013-09-24 | GSE51100 | GEO

Autoimmune antigen and serum factor antigen reactivity in a cohort of patients with systemic lupus erythematosus (SLE) and healthy controls from the ABCoN cohort.

Project description:The aim of the study was to test the hypothesis that SLE patient sera contains IgG reactivity to serum factor antigens concomitant with prototypical autoimmne antigens. We diluted patient sera 1:250 and incubated dilutions on a nitrocellulose-platform array printed with whole protein antigens. In this study, serum from 45 individuals (subsetted into high and low interferon signature as well as healthy control categories) was profiled for IgG autoantibody reactivity to whole protein autoimmune and serum factor antigens. SLE and specifically IFN high patient sera was found using the significance analysis of microarrays (SAM) algorithm to be significantly more reactive with prototypical autoimmune antigens and select serum factor array antigens.

2013-09-24 | E-GEOD-51100 | biostudies-arrayexpress

Autoimmune antigen and serum factor antigen reactivity in a cohort of patients with autoimmune polyendocrinopathy syndrome type 1(APS-1) and healthy controls.

Project description:The aim of the study was to test the hypothesis that APS-1 patient sera contains IgG reactivity to serum factor antigens concomitant with prototypical autoimmne antigens. We diluted patient sera 1:250 and incubated dilutions on a nitrocellulose-platform array printed with whole protein antigens. In this study, serum from 14 ndividuals (subsetted into APS-1 patient and healthy control categories) was profiled for IgG autoantibody reactivity to whole protein autoimmune and serum factor antigens. APS-1 patient sera was found using the significance analysis of microarrays (SAM) algorithm to be significantly more reactive with prototypical cytokine antigens previously identified as targets of autoantibodies.

2013-09-24 | E-GEOD-51101 | biostudies-arrayexpress

Autoimmune antigen and serum factor antigen reactivity in a cohort of patients with autoimmune polyendocrinopathy syndrome type 1(APS-1) and healthy controls.

2013-09-24 | GSE51101 | GEO

Parasite specific 7SL-derived small RNA is an effective target for diagnosis of active trypanosomiasis infection

Project description:Human and animal African trypanosomiasis (HAT & AAT, respectively) remain a significant health and economic issue across much of sub-Saharan Africa. Effective control of AAT and potential eradication of HAT requires affordable, sensitive and specific diagnostic tests that can be used in the field. Small RNAs in the blood or serum are attractive disease biomarkers due to their stability, accessibility and available technologies for detection. Using RNAseq, we have identified a trypanosome specific small RNA to be present at high levels in the serum of infected cattle. The small RNA is derived from the non-coding 7SL RNA of the peptide signal recognition particle and is detected in the serum of infected cattle at significantly higher levels than in the parasite, suggesting active processing and secretion. We show effective detection of the small RNA in the serum of infected cattle using a custom qRT-PCR assay. Strikingly, the RNA can be detected before microscopy detection of parasitaemia in the blood, and it can also be detected during remission periods of infection when no parasitaemia is detectable by microscopy. However, RNA levels rapidly drop following treatment with trypanocides, demonstrating accurate prediction of active infection. While the small RNA sequence is conserved between different species of trypanosome, nucleotide differences within the sequence allow generation of highly specific assays that can distinguish between infections with Trypanosoma brucei, Trypanosoma congolense and Trypanosoma vivax. Finally, we demonstrate effective detection of the small RNA directly from serum, without the need for pre-processing, with a single step qRT-PCR assay. Our findings identify a species-specific trypanosome small RNA that can be detected at high levels in the serum of cattle with active parasite infections. This provides the basis for the development of a cheap, non-invasive and highly effective diagnostic test for trypanosomiasis.

2019-02-11 | GSE122858 | GEO

Histone protein and peptide reactivity within patients with systemic lupus erythematosus (SLE) from the ABCoN cohort

Project description:The aim of the study was to test the hypothesis that IFN high SLE patient sera is more reactive to whole histone proteins and post-translationally modified histone peptides than IFN low patient sera. We diluted patient sera 1:250 and incubated dilutions on a nitrocellulose-platform array printed with whole protein and peptide histone antigens. In this study, serum from 30 patients subsetted into high and low interferon signature categories were profiled for IgG autoantibody reactivity to whole histone proteins, unmodified and post-translationally modified histone peptides. IFN high patient sera was found using the significance analysis of microarrays (SAM) algorithm to be significantly more reactive with whole histone and modified histone peptide antigens.

2011-12-02 | E-GEOD-34070 | biostudies-arrayexpress

Detection of hypermethylated circulating serum DNA in metastatic breast cancer and confirmation by the cMethDNA assay

Project description:The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. We developed cMethDNA, a quantitative multiplexed methylation specific PCR assay for a panel of ten genes, discovered through whole genome methylation array analysis of serum DNA. Cancer-specific methylated DNA was detected in training and test sets of recurrent Stage 4 patient sera with a sensitivity of >90% and a specificity of >96%. A core methylation signature was retained in serum, primary and metastatic tissues throughout the course of the disease, and the cMethDNA assay levels reflected patient response to chemotherapy. Together, our data suggest that the cMethDNA assay can provide a sensitive tool to detect minute levels of tumor DNA present in a vast excess of normal DNA in serum. Samples used: 11 cancer sera,,4 pools of normal leukocytes (5 donors per pool), 6 normal breast tissues microdissected, adjacent to tumor, 15 normal breast tissues, organoid preparations

2014-03-01 | E-GEOD-52621 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data